Related Experiment Video
Updated: Jun 20, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients
Won Young Tak1, Soo Young Park, Min Kyu Jung
1Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Daegu, Korea.
Abstract:
As a pyrimidine analog with potent and sustained antiviral activity against hepatitis B virus, clevudine has been known to have no effect on mitochondrial structure, DNA content, or function. There is little information on the side effects of clevudine, which has not been approved for the treatment of chronic hepatitis B outside of South Korea. We report here two cases of chronic hepatitis B patients who experienced mitochondrial myopathy after clevudine medication. These cases raise concerns about the safety profile of clevudine for the treatment of chronic hepatitis B.
Related Concept Videos
Hepatitis
Hepatic Encephalopathy
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Cytomegalovirus Disease
